A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level...

Area of Science:

• Hepatology
• Oncology
• Virology

Background:

• Hepatocellular carcinoma (HCC) incidence is high in chronic hepatitis C patients.
• Alpha-fetoprotein (AFP) is a widely used diagnostic marker for HCC.
• Elevated AFP without HCC indicates a high-risk group for HCC development.

Purpose of the Study:

• To investigate the effect of interferon (IFN) on AFP levels in chronic hepatitis C patients.
• To assess whether IFN therapy can reduce elevated AFP levels in patients at high risk for HCC.

Main Methods:

• 40 chronic hepatitis C patients without HCC were divided into high AFP (>10 ng/dl) and low AFP (<=10 ng/dl) groups.
• 27 patients received IFN therapy, and 13 received Stronger Neo-minophagen C (SNMC) as a control.
• Clinical parameters and AFP levels were monitored before and after treatment.

Main Results:

• IFN therapy significantly reduced AFP levels (30.03 to 12.65 ng/ml, P=0.0034).
• SNMC therapy did not significantly alter AFP levels (29.70 to 39.17 ng/ml).
• Alanine aminotransferase levels decreased in both IFN and SNMC groups.

Conclusions:

• IFN therapy effectively reduces AFP levels in chronic hepatitis C patients.
• Reduced AFP levels with IFN may indicate a potential role in preventing hepatocarcinogenesis.
• IFN may be a valuable therapeutic strategy for managing high-risk HCC patients.